S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Arvinas Stock Forecast, Price & News

-0.25 (-0.33%)
(As of 11/30/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
384,806 shs
Average Volume
433,899 shs
Market Capitalization
$4.00 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Arvinas logo

About Arvinas

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.


Arvinas (NASDAQ:ARVN) Shares Down 3.9%
November 24, 2021 |  americanbankingnews.com
Arvinas (NASDAQ:ARVN) Stock Price Up 5.4%
November 19, 2021 |  americanbankingnews.com
Notable Arvinas Insider Trades $2.0M In Company Stock
November 18, 2021 |  finance.yahoo.com
Notable Arvinas Insider Makes $11M Sale - Yahoo Finance
November 16, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$21.80 million
Book Value
$13.27 per share


Net Income
$-119.33 million
Net Margins
Pretax Margin




Free Float
Market Cap
$4.00 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.23 out of 5 stars

Medical Sector

336th out of 1,390 stocks

Pharmaceutical Preparations Industry

154th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas
or view top-rated stocks.

How has Arvinas' stock been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARVN shares have increased by 71.6% and is now trading at $75.61.
View which stocks have been most impacted by COVID-19

Are investors shorting Arvinas?

Arvinas saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 1,550,000 shares, a drop of 33.2% from the October 31st total of 2,320,000 shares. Based on an average trading volume of 329,700 shares, the days-to-cover ratio is currently 4.7 days. Approximately 3.6% of the company's stock are sold short.
View Arvinas' Short Interest

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Arvinas

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) announced its earnings results on Wednesday, November, 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of $2.13 by $3.07. The firm had revenue of $9.28 million for the quarter, compared to analyst estimates of $26.89 million. Arvinas had a negative trailing twelve-month return on equity of 27.02% and a negative net margin of 794.97%. The business's revenue was up 22.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.79) earnings per share.
View Arvinas' earnings history

What price target have analysts set for ARVN?

16 brokerages have issued 12-month price targets for Arvinas' stock. Their forecasts range from $93.00 to $170.00. On average, they expect Arvinas' stock price to reach $128.44 in the next year. This suggests a possible upside of 69.9% from the stock's current price.
View analysts' price targets for Arvinas
or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.20%), Bellevue Group AG (4.24%), New Leaf Venture Partners L.L.C. (2.47%), Canaan Partners IX LLC (1.48%), Geode Capital Management LLC (1.44%) and Morgan Stanley (1.41%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends for Arvinas

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, New Leaf Venture Partners L.L.C., Deutsche Bank AG, Point72 Asset Management L.P., Renaissance Technologies LLC, Millennium Management LLC, Eagle Asset Management Inc., and Rock Springs Capital Management LP. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or view top insider-selling stocks.

Which major investors are buying Arvinas stock?

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Voya Investment Management LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC, and Wasatch Advisors Inc.. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $75.61.

How much money does Arvinas make?

Arvinas has a market capitalization of $4.00 billion and generates $21.80 million in revenue each year. The company earns $-119.33 million in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 179 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

Where are Arvinas' headquarters?

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.